Marketing status and drug analysis of cartegravir sodium tablets

Cabotegravir sodium tablets (cabotegravir), as an innovative HIV-1 integrase strand transfer inhibitor (INSTI), has attracted much attention since its inception. The drug, used in combination with rilpivirine, provides a new short-term treatment for HIV-1 infection in adults and adolescents aged 12 and older who weigh at least 35kg.

Especially for patients with stable virological suppression, no history of treatment failure, and no resistance to related drugs, cartegravir sodium tablets are undoubtedly an important treatment option. In addition, it is also suitable for short-term pre-exposure prophylaxis (PrEP), which helps reduce the risk of HIV-1 infection through sexual behavior and provides a new means of preventing AIDS.

In terms of marketing status, Cartegravir Sodium Tablets was approved on2021year1month21 It was approved by the U.S. Food and Drug Administration (FDA) and officially launched under the trade name Vocabria. In July 2023, this drug was successfully launched in my country, with the trade name Wankairui. Currently, there is no generic version of canegravir sodium tablets on the market, and the price of the European version of the original drug is about RMB 8,000. Unfortunately, this drug has not yet been included in medical insurance. For patients in need of medication, they may need to consult local hospital pharmacies or regular overseas medical consulting agencies to obtain it.

Of course, any drug has its possible side effects, and cartegravir sodium tablets are no exception. Common side effects include headache, nausea, anxiety, abnormal dreams, and difficulty falling asleep, etc. These symptoms may have a certain impact on the patient's daily life. Serious side effects may include depression or mood changes, rash, fever, extreme fatigue, muscle or joint pain, etc., and there may even be serious reactions such as swelling of the eyes, lips, tongue or mouth, and difficulty breathing. Therefore, patients should pay close attention to their body's reaction when taking castegravir sodium tablets. Once the above symptoms occur, they should seek medical treatment immediately and seek professional help.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212887s008lbl.pdf